Bolt Biotherapeutics, Inc. (BOLT) Dividend History

Bolt Biotherapeutics, Inc. is a biotechnology company focused on developing tumor-activated immunotherapies. They utilize their proprietary Amplify-They-Cell platform to design therapies that activate the immune system specifically within the tumor microenvironment, aiming to enhance cancer treatment efficacy while minimizing systemic side effects.

900 Chesapeake Drive, Redwood City, CA, 94063
Phone: 650-665-9295
Website: https://www.boltbio.com

Dividend History

Bolt Biotherapeutics, Inc. currently does not pay dividends

Company News

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Bolt Biotherapeutics announced positive results from a Phase 1 study of its cancer immunotherapy BDC-3042, which showed favorable safety, biological activity, and signs of anti-tumor activity. The company is seeking a partner to advance the development of BDC-3042.

GlobeNewswire Inc.
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

Bolt Biotherapeutics presented positive preclinical data for its next-generation cancer immunotherapy candidate BDC-4182 and key learnings from its Phase 1 trial of BDC-1001, suggesting that enhanced immune activation could lead to greater efficacy.

GlobeNewswire Inc.
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Bolt Biotherapeutics, Inc. is facing a securities fraud lawsuit alleging that the company made false and misleading statements about the effectiveness of its drug BDC-1001 in treating certain cancers, and overstated the commercial prospects of its drug pipeline.

GlobeNewswire Inc.
BOLT DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action – BOLT

Bolt Biotherapeutics, Inc. is facing a securities class action lawsuit due to allegedly making false and/or misleading statements about the effectiveness of its cancer treatment drug BDC-1001, which could lead to damages for investors.

GlobeNewswire Inc.
BOLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Bolt Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

A class action lawsuit has been filed against Bolt Biotherapeutics, Inc. (BOLT) alleging that the company made materially false and misleading statements about the effectiveness of its product BDC-1001, overstating its clinical and commercial prospects.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 20:03:35 UTC